Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Receivables: 2017-2024

Historic Change in Receivables for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $155.0 million.

  • Protagonist Therapeutics' Change in Receivables rose 1550.00% to $165.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $155.0 million, marking a year-over-year increase of 1451.55%. This contributed to the annual value of $155.0 million for FY2024, which is 1451.55% up from last year.
  • Protagonist Therapeutics' Change in Receivables amounted to $155.0 million in FY2024, which was up 1,451.55% from $10.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Change in Receivables ranged from a high of $155.0 million in FY2024 and a low of -$4.3 million during FY2020.
  • Over the past 3 years, Protagonist Therapeutics' median Change in Receivables value was $10.0 million (recorded in 2023), while the average stood at $54.5 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Change in Receivables tumbled by 299.68% in 2020, and later spiked by 1,451.55% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Change in Receivables (Yearly) stood at -$4.3 million in 2020, then soared by 80.13% to -$860,000 in 2021, then crashed by 80.93% to -$1.6 million in 2022, then soared by 742.03% to $10.0 million in 2023, then soared by 1,451.55% to $155.0 million in 2024.